Renal denervation in an animal model of diabetes and hypertension: Impact on the autonomic nervous system and nephropathy

Imagem de Miniatura
Arquivos
art_DIAS_Renal_denervation_in_an_animal_model_of_diabetes_2011.PDF (360.95 KB)
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2011
Editora
BIOMED CENTRAL LTD
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
DIAS, Lucinara D.
CASALI, Karina R.
LEGUISAMO, Natalia M.
AZAMBUJA, Felipe
SOUZA, Martina S.
OKAMOTO, Maristela
MACHADO, Ubiratan F.
SCHAAN, Beatriz D.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CARDIOVASCULAR DIABETOLOGY, v.10, article ID 33, 8p, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: The effects of renal denervation on cardiovascular reflexes and markers of nephropathy in diabetic-hypertensive rats have not yet been explored. Methods: Aim: To evaluate the effects of renal denervation on nephropathy development mechanisms (blood pressure, cardiovascular autonomic changes, renal GLUT2) in diabetic-hypertensive rats. Forty-one male spontaneously hypertensive rats (SHR) similar to 250 g were injected with STZ or not; 30 days later, surgical renal denervation (RD) or sham procedure was performed; 15 days later, glycemia and albuminuria (ELISA) were evaluated. Catheters were implanted into the femoral artery to evaluate arterial pressure (AP) and heart rate variability (spectral analysis) one day later in conscious animals. Animals were killed, kidneys removed, and cortical renal GLUT2 quantified (Western blotting). Results: Higher glycemia (p < 0.05) and lower mean AP were observed in diabetics vs. nondiabetics (p < 0.05). Heart rate was higher in renal-denervated hypertensive and lower in diabetic-hypertensive rats (384.8 +/- 37, 431.3 +/- 36, 316.2 +/- 5, 363.8 +/- 12 bpm in SHR, RD-SHR, STZ-SHR and RD-STZ-SHR, respectively). Heart rate variability was higher in renal-denervated diabetic-hypertensive rats (55.75 +/- 25.21, 73.40 +/- 53.30, 148.4 +/- 93 in RD-SHR, STZ-SHR-and RD-STZ-SHR, respectively, p < 0.05), as well as the LF component of AP variability (1.62 +/- 0.9, 2.12 +/- 0.9, 7.38 +/- 6.5 in RD-SHR, STZ-SHR and RD-STZ-SHR, respectively, p < 0.05). GLUT2 renal content was higher in all groups vs. SHR. Conclusions: Renal denervation in diabetic-hypertensive rats improved previously reduced heart rate variability. The GLUT2 equally overexpressed by diabetes and renal denervation may represent a maximal derangement effect of each condition.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/23964
Referências
  1. Schaan BD, 2004, BRAZ J MED BIOL RES, V37, P1895, DOI 10.1590/S0100-879X2004001200016
  2. Vestri S, 2001, J MEMBRANE BIOL, V182, P105, DOI 10.1007/s00232-001-0036-y
  3. PAGANI M, 1986, CIRC RES, V59, P178
  4. Stauss HM, 2007, CLIN EXP PHARMACOL P, V34, P362, DOI 10.1111/j.1440-1681.2007.04588.x
  5. Ferguson RE, 2005, PROTEOMICS, V5, P566, DOI 10.1002/pmic.200400941
  6. Montano N, 2009, NEUROSCI BIOBEHAV R, V33, P71, DOI 10.1016/j.neubiorev.2008.07.006
  7. DiBona GF, 2005, AM J PHYSIOL-REG I, V289, pR633, DOI 10.1152/ajpregu.00258.2005
  8. OLIVEIRA VLL, 1992, HYPERTENSION, V19, P17
  9. DallAgo P, 1997, BRAZ J MED BIOL RES, V30, P119
  10. Schaan BD, 2005, AUTON NEUROSCI-BASIC, V117, P54, DOI 10.1016/j.autneu.2004.11.001
  11. STAUSS HM, 1995, J AUTONOM NERV SYST, V54, P145, DOI 10.1016/0165-1838(94)00000-A
  12. MALLIANI A, 1991, CIRCULATION, V84, P482
  13. Fazan R, 2005, AM J PHYSIOL-HEART C, V289, pH1968, DOI 10.1152/ajpheart.01224.2004
  14. Asada T, 1997, AM J PHYSIOL-RENAL, V273, pF27
  15. Balbinott AW, 2005, J CARDIOVASC PHARM, V1, P1
  16. Bertoluci MC, 1996, NEPHRON, V74, P189
  17. BOKU A, CARDIOVASC DIABETOL, V9, P78
  18. CERUTTI C, 1991, AM J PHYSIOL, V261, pH1292
  19. CHANG KSK, 1986, J MOL CELL CARDIOL, V18, P617, DOI 10.1016/S0022-2828(86)80969-5
  20. DAI S, 1994, CAN J CARDIOL, V10, P562
  21. Schaan BD, 2003, AUTON NEUROSCI-BASIC, V104, P88, DOI 10.1016/S1566-0702(02)00295-3
  22. ESLER MD, LANCET, V376, P1903
  23. Farah VDA, 2007, CLINICS, V62, P477, DOI 10.1590/S1807-59322007000400015
  24. Farah VMA, 1999, BRAZ J MED BIOL RES, V32, P361, DOI 10.1590/S0100-879X1999000300018
  25. Fazan R, 1999, J HYPERTENS, V17, P489, DOI 10.1097/00004872-199917040-00006
  26. Fazan R, 1997, HYPERTENSION, V30, P632
  27. FELTEN SY, 1982, BRAIN RES BULL, V8, P593, DOI 10.1016/0361-9230(82)90086-7
  28. Freitas HS, 2007, NEPHRON PHYSIOL, V105, P42, DOI 10.1159/000098442
  29. KILKENNY C, J PHARM PHARMACOTHER, V1, P94
  30. Kopp UC, 2008, AM J PHYSIOL-REG I, V295, pR1882, DOI 10.1152/ajpregu.90529.2008
  31. Lee J Y, 1983, J Hypertens, V1, P381, DOI 10.1097/00004872-198312000-00010
  32. MAEDA CY, 1995, HYPERTENSION, V26, P1100
  33. *NIH, 1996, GUID CAR US LAB AN
  34. Oliveira VLL, 1999, HYPERTENSION, V34, P813
  35. Osborn JL, 1997, CLIN EXP PHARMACOL P, V24, P72, DOI 10.1111/j.1440-1681.1997.tb01786.x
  36. PARVING HH, 1981, DIABETES CARE, V4, P459, DOI 10.2337/diacare.4.4.459
  37. Ramchandra R, 2002, AM J PHYSIOL-REG I, V282, pR603
  38. RODGERS RL, 1986, CAN J PHYSIOL PHARM, V64, P1177
  39. SALMAN IM, NEUROUROL URODYNAM, V30, P438
  40. Schaan BD, 2001, HORM METAB RES, V33, P664
  41. Schaan BD, 1997, BRAZ J MED BIOL RES, V30, P1081
  42. Schaan Beatriz D'Agord, 2005, Nephron Physiology, V100, P43
  43. SCHMIDT RE, 1982, DIABETES, V31, P761, DOI 10.2337/diabetes.31.9.761
  44. Souza MS, 2008, BRAZ J MED BIOL RES, V41, P960
  45. SUNDKVIST G, 1993, DIABETES CARE, V16, P773, DOI 10.2337/diacare.16.5.773
  46. WIDDOP RE, 1990, J HYPERTENS, V8, P269
  47. Xie HH, 2006, EUR J PHARMACOL, V543, P77, DOI 10.1016/j.ejphar.2006.05.034

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/59